 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTATM loncastuximab tesirine-lpyl Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL were presented at the 2021 American Society of Clinical Oncology ASCO Annual 